Share Email Print
cover

Proceedings Paper

Photodynamic therapy in two murine tumor models with sulfonated aluminum phthalocyanine
Author(s): Hong-Yu Yu; Rong-Chun Dong; Ji-Yao Chen; Huai-Xin Cai
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Photodynamic therapy (PDT) with sulfonated aluminum phthalocyanine (AlSPC), i.e., AlSPC-PDT, in two murine tumor models is reported here. The encouraging therapy results were observed in S180 fibrosarcoma transplanted in white mice of the Kunming line and in human hepatocellular carcinoma transplanted in balb/c nu/nu nude mice. The experimental tumors in the mice were chosen of those 0.5 - 0.8 cm in diameter and 0.4 - 0.7 cm in thickness. Photofrin II (PII) and Photosensitizing drug-007 (PSD-007), two kinds of porphyrin derivative dyes, were chosen as the contrast photosensitizers of AlSPC. A dose of 10 mg/kg AlSPC or PII or PSD-007 was given (iv). The dose of light (600 - 750 nm) was 180 J/cm2. `Cure (short-term)' was defined as regression of neoplastic tissue to a non-palpable tumor within 14 days after PDT. `Cure (long-term)' was defined as absence of local tumor tissue and tumor metastasis on gross and microscopic examinations within 107 days after PDT. The curative results suggest that AlSPC may be a more effective sensitizer than both PII and PSD-007.

Paper Details

Date Published: 5 March 1993
PDF: 7 pages
Proc. SPIE 1616, International Conference on Photodynamic Therapy and Laser Medicine, (5 March 1993); doi: 10.1117/12.137032
Show Author Affiliations
Hong-Yu Yu, Second Military Medical Univ. (China)
Rong-Chun Dong, Second Military Medical Univ. (China)
Ji-Yao Chen, Fudan Univ. (China)
Huai-Xin Cai, Fudan Univ. (China)


Published in SPIE Proceedings Vol. 1616:
International Conference on Photodynamic Therapy and Laser Medicine

© SPIE. Terms of Use
Back to Top